MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers
Authors:
Open Access
- 3 December 2021
- journal article
- review article
- Published by Elsevier in Genes & Diseases
- Vol. 9 (4) , 849-867
Abstract
No abstract availableKeywords
Funding Information
- Tabriz University of Medical Sciences
This publication has 196 references indexed in Scilit:
- MicroRNA‐146 represses endothelial activation by inhibiting pro‐inflammatory pathwaysEMBO Molecular Medicine, 2013
- Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimatesThe Lancet, 2013
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia DevelopmentCancer Cell, 2011
- Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon‐mediated rejection genesInternational Journal of Cancer, 2011
- Role of microRNA-155 in autoimmunityCytokine & Growth Factor Reviews, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Systematic Proteome Analysis Identifies Transcription Factor YY1 as a Direct Target of miR-34aJournal of Proteome Research, 2010
- Role of STAT3 and GATA-1 interactions in γ-globin gene expressionExperimental Hematology, 2009
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- BIC and miR‐155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomasThe Journal of Pathology, 2005